var data={"title":"Vernakalant: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vernakalant: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/743110?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vernakalant-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vernakalant: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51109367\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Brinavess</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502587\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Class III</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502893\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Atrial fibrillation (pharmacologic cardioversion):</b> IV: Initial: 3 mg/kg (maximum dose: 339 mg) over 10 minutes. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second infusion of 2 mg/kg (maximum dose: 226 mg) over 10 minutes may be administered (Camm 2011; Kowey 2009; Pratt 2010; Roy 2008; Simon 2017). If hemodynamically stable atrial flutter is observed after the first infusion, the second infusion may be administered to convert to sinus rhythm. Cumulative doses &gt;5 mg/kg should not be administered within 24 hours; cumulative doses &gt;565 mg have not been evaluated. <b>Note:</b> Stop the infusion promptly and do not administer second dose if these events occur shortly after the first infusion: Sudden drop in blood pressure or heart rate, with or without symptomatic hypotension or bradycardia; hypotension; bradycardia; ECG changes (such as a clinically meaningful sinus pause, complete heart block, new bundle branch block, significant prolongation of the QRS or QT interval, changes consistent with ischemia, infarction, or ventricular arrhythmia).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50992518\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989768\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; use caution in advanced hepatic impairment (has not been adequately studied)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502898\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51109368\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51109369\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Intravenous, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brinavess: 20 mg/mL (25 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25246248\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502917\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV infusion only in a monitored clinical setting. Do not administer by IV push or bolus. Must dilute concentrate before use. Infuse over 10 minutes using an infusion pump (preferred) or a syringe pump. If conversion to sinus rhythm occurs during either the first or second infusion, continue the infusion to completion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502588\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (pharmacologic cardioversion): </b> Rapid conversion of recent onset atrial fibrillation to sinus rhythm for nonsurgical (atrial fibrillation duration: &le;7 days) and postcardiac surgery patients (atrial fibrillation duration: &le;3 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46503300\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (4% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sneezing (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial flutter (2% to 10%), bradycardia (2% to 8%), ventricular arrhythmia (&le;6%), hypertension (1% to 2%), first degree atrioventricular block (1%), ventricular tachycardia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (7%), dizziness (3% to 4%), fatigue (1% to 3%), feeling hot (2%), infusion site pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis (3%), pruritus (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 6%), oral paresthesia (2%), vomiting (1%), diarrhea (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4%), nasal discomfort (2%), dyspnea (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distress, abdominal pain, agitation, altered sense of smell, angina pectoris, anosmia, anxiety, arterial thrombosis, arthralgia, asphyxia, atrioventricular block, back pain, blurred vision, bowel urgency, cardiogenic shock, catheter site erythema, chest discomfort, chest pain, chills, confusion, constipation, cystitis, decreased hemoglobin, decreased serum potassium, decreased urine output, drowsiness, dyspepsia, ecchymoses, erythema, eye irritation, fever, flushing, hematuria, hyperkalemia, hyperthyroidism, hyperventilation, hypoesthesia, hypokalemia, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lacrimation, increased serum AST, increased serum creatinine, injection site pruritus, injection site reaction, insomnia, irritation at injection site, left bundle branch block, limb pain, malaise, mitral valve insufficiency, muscle spasm, musculoskeletal pain, myalgia, nasal congestion, nasopharyngitis, nodal arrhythmia, oral hypoesthesia, oropharyngeal pain, orthopnea, pain at injection site, pallor, palpitations, peripheral edema, prolonged Q-T interval on ECG, pulmonary edema, rales, rhinitis, rhinorrhea, right bundle branch block, sinoatrial arrest, sinus bradycardia, skin rash, supraventricular extrasystole, supraventricular tachycardia, syncope, throat irritation, upper respiratory tract infection, urinary retention, urinary tract infection, ventricular fibrillation, ventricular fibrillation, ventricular premature contractions, visual impairment, weakness, widened QRS complex on ECG, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502591\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vernakalant or any component of the formulation; severe aortic stenosis; systolic blood pressure &lt;100 mm Hg; heart failure class NYHA III or NYHA IV; acute coronary syndrome or acute decompensated heart failure within the last 30 days; significant prolonged QT at baseline (eg, uncorrected &gt;440 msec); congenital or acquired long QT syndrome; severe bradycardia, sinus node dysfunction; second- or third-degree heart block in the absence of a properly functioning pacemaker; use of IV class I or class III antiarrhythmics within 4 hours prior to or after vernakalant administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502592\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial flutter: May be associated with a higher incidence of converting to atrial flutter within the first 2 hours postdose; risk is increased in patients taking class I anti-arrhythmics. If atrial flutter occurs with signs of hemodynamic instability or development of 1:1 atrioventricular (AV) conduction, discontinuation should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: Serious bradycardia has been reported during or following infusion (most occurring soon after conversion to sinus rhythm). If bradycardia occurs, discontinue therapy promptly; however, some events of bradycardia requiring electrical pacing have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Hypotension, some serious and/or severe, has been reported during and immediately following infusion. Observe patients carefully, assessing vital signs and continuous cardiac rhythm monitoring, during infusion and for &ge;2 hours after administration. If hypotension occurs or a sudden drop in blood pressure or heart rate, with or without symptomatic hypotension or bradycardia occurs, discontinue promptly. Resuscitation equipment and the capability to place a temporary pacemaker should be readily available. Use with caution in patients with systolic blood pressure (SBP) &lt;105 mm Hg at the time of initiation of infusion (these patients have a 3-fold increased incidence of hypotension).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: May occur. Use is not recommended in patients with a family history of long QT syndrome unless a diagnosis of long QT syndrome has been definitively ruled out. Discontinue use promptly if ECG changes (eg, clinically meaningful sinus pause, complete heart block, new bundle branch block, significant prolongation of the QRS or QT interval, changes consistent with ischemia, infarction, ventricular arrhythmia) occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use caution in patients with HF class NYHA I or II. Use in patients with previously documented LVEF &le;35% is not recommended. Use caution in patients with valvular heart disease (higher incidence of ventricular arrhythmia and bradycardia in the first 2 hours postdose). Use is not recommended in patients with clinically meaningful hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is not recommended in advanced hepatic impairment (not adequately studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Correct potassium levels prior to use in patients with uncorrected hypokalemia (ie, serum potassium &lt;3.5 mmol/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium: Some products may contain sodium. Use caution in patients on a sodium controlled diet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not recommended for conversion of atrial flutter to sinus rhythm. Patients should be anticoagulated in accordance to guidelines before and after treatment with vernakalant to reduce the risk for thromboembolic complications after return to normal sinus rhythm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46507365\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46507362\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=116881&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502589\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Due to lack of data, current guidelines recommend using vernakalant in pregnant women only when other attempts at cardioversion have failed (ESC [Regitz-Zagrosek 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502590\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if vernakalant is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502920\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs/symptoms of a sudden decrease in blood pressure or heart rate or significant QT prolongation for the duration of the first infusion and for at least 15 minutes after the completion of the infusion with assessment of vital signs and continuous cardiac rhythm monitoring; if a second dose is administered, further monitor for the duration of the second infusion; monitor for at least 2 hours after cessation of infusion, and until clinical and ECG parameters have stabilized; potassium (prior to initiation of therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502830\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Anti-arrhythmic that acts preferentially on the atrial with limited effects on ventricular tissues. It is a multi-ion channel blocker, which inhibits several potassium and sodium currents. This results in prolongation of atrial refractoriness and rate dependent slowing of atrial conduction to suppress atrial re-entry. It has little impact on currents involved in ventricular repolarization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502870\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~2 L/kg; extensively and rapidly distributed in the body</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 37% to 47%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via CYP2D6 O-demethylation in CYP2D6 extensive metabolizers to the active metabolite RSD1385 (Finnin 2010) and glucuronidation in CYP2D6 poor metabolizers</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~3 hours (CYP2D6 extensive metabolizers) and ~5.5 hours (CYP2D6 poor metabolizers)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46426599\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Brinavess (AT, CH, CO, CY, CZ, DE, DK, EE, ES, FI, GR, HR, HU, IE, IL, JO, LB, LT, LU, LV, MT, NL, NO, PL, PT, QA, RO, SE, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brinavess (vernakalant) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21232669\"></a>Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. <i>J Am Coll Cardiol</i>. 2011;57(3):313-321. doi: 10.1016/j.jacc.2010.07.046.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/21232669/pubmed\" target=\"_blank\" id=\"21232669\">21232669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finnin M. Vernakalant: A novel agent for the termination of atrial fibrillation. <i>Am J Health Syst Pharm</i>. 2010;67(14):1157-1164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/20592320/pubmed\" target=\"_blank\" id=\"20592320\">20592320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19948506\"></a>Kowey PR, Dorian P, Mitchell LB, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.<i> Circ Arrhythm Electrophysiol</i>. 2009;2(6):652-659. doi: 10.1161/CIRCEP.109.870204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/19948506/pubmed\" target=\"_blank\" id=\"19948506\">19948506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21029824\"></a>Pratt CM, Roy D, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial (ACT-III) Investigators. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. <i>Am J Cardiol</i>. 2010;106(9):1277-1283. doi: 10.1016/j.amjcard.2010.06.054.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/21029824/pubmed\" target=\"_blank\" id=\"21029824\">21029824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21873418\"></a>Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18332267\"></a>Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. <i>Circulation</i>. 2008;117(12):1518-1525. doi: 10.1161/CIRCULATIONAHA.107.723866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/18332267/pubmed\" target=\"_blank\" id=\"18332267\">18332267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28175295\"></a>Simon A, Niederdoeckl J, Skyllouriotis E, et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. <i>Europace</i>. 2017;19(2):233-240. doi: 10.1093/europace/euw052.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vernakalant-drug-information/abstract-text/28175295/pubmed\" target=\"_blank\" id=\"28175295\">28175295</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 116881 Version 4.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F51109367\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46502587\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46502893\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50992518\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989768\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46502898\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F51109368\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F51109369\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F25246248\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46502917\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46502588\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46503300\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46502591\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46502592\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46507365\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46507362\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46502589\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46502590\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46502920\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46502830\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46502870\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46426599\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/116881|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vernakalant-patient-drug-information\" class=\"drug drug_patient\">Vernakalant: Patient drug information</a></li></ul></div></div>","javascript":null}